PE20181332A1 - Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos - Google Patents
Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticosInfo
- Publication number
- PE20181332A1 PE20181332A1 PE2018000199A PE2018000199A PE20181332A1 PE 20181332 A1 PE20181332 A1 PE 20181332A1 PE 2018000199 A PE2018000199 A PE 2018000199A PE 2018000199 A PE2018000199 A PE 2018000199A PE 20181332 A1 PE20181332 A1 PE 20181332A1
- Authority
- PE
- Peru
- Prior art keywords
- sedation
- treatment
- methods
- use during
- critical care
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010039897 Sedation Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000036280 sedation Effects 0.000 title 1
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical group C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 abstract 1
- 229950004346 gaboxadol Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203748P | 2015-08-11 | 2015-08-11 | |
| US201562203731P | 2015-08-11 | 2015-08-11 | |
| US14/834,027 US9399034B1 (en) | 2015-08-11 | 2015-08-24 | Methods of sedation during critical care treatment |
| US15/185,650 US9717716B2 (en) | 2015-08-11 | 2016-06-17 | Methods of sedation during critical care treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181332A1 true PE20181332A1 (es) | 2018-08-20 |
Family
ID=59687449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000199A PE20181332A1 (es) | 2015-08-11 | 2016-08-02 | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180235942A1 (OSRAM) |
| EP (1) | EP3334427A4 (OSRAM) |
| JP (1) | JP6857647B2 (OSRAM) |
| KR (1) | KR20180048707A (OSRAM) |
| CN (1) | CN108135889A (OSRAM) |
| AU (1) | AU2016304737B2 (OSRAM) |
| CA (1) | CA2994952A1 (OSRAM) |
| CO (1) | CO2018002534A2 (OSRAM) |
| IL (1) | IL257296B2 (OSRAM) |
| MX (1) | MX394213B (OSRAM) |
| PE (1) | PE20181332A1 (OSRAM) |
| TW (1) | TWI763632B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391708B (es) | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| EP3833351A4 (en) | 2018-09-20 | 2021-10-13 | Ovid Therapeutics Inc. | USE OF GABOXADOL FOR THE TREATMENT OF GILLES DE LA TOURETTE SYNDROME, TICS AND STATTING |
| BR112021009944A2 (pt) | 2018-11-21 | 2021-08-17 | Certego Therapeutics Inc. | gaboxadol para reduzir risco de suicídio e alívio rápido de depressão |
| KR20210105387A (ko) | 2018-12-17 | 2021-08-26 | 오비드 테라퓨틱스 인크. | 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용 |
| JP2023526439A (ja) | 2020-05-20 | 2023-06-21 | セルテゴ セラピューティクス インコーポレイテッド | 精神障害の処置のための環重水素化ガボキサドールおよびその使用 |
| US20220218740A1 (en) * | 2020-10-25 | 2022-07-14 | Vaporworks Nursing Anesthesia Inc. | Opioid-free compositions for anesthesiological applications and related methods and systems |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071933A (en) * | 1999-12-03 | 2000-06-06 | Diversified Medical Innovations, Inc. | Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use |
| WO2005063248A1 (en) * | 2003-12-22 | 2005-07-14 | Sepracor Inc. | Modafinil combination therapy for improving sleep quality |
| ATE454140T1 (de) * | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
| US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| US9399034B1 (en) * | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2016
- 2016-08-02 AU AU2016304737A patent/AU2016304737B2/en not_active Ceased
- 2016-08-02 JP JP2018506932A patent/JP6857647B2/ja not_active Expired - Fee Related
- 2016-08-02 CN CN201680059253.3A patent/CN108135889A/zh active Pending
- 2016-08-02 KR KR1020187007146A patent/KR20180048707A/ko not_active Withdrawn
- 2016-08-02 CA CA2994952A patent/CA2994952A1/en active Pending
- 2016-08-02 EP EP16835628.5A patent/EP3334427A4/en not_active Withdrawn
- 2016-08-02 MX MX2018001720A patent/MX394213B/es unknown
- 2016-08-02 PE PE2018000199A patent/PE20181332A1/es not_active Application Discontinuation
- 2016-08-02 US US15/751,680 patent/US20180235942A1/en not_active Abandoned
- 2016-08-10 TW TW105125498A patent/TWI763632B/zh not_active IP Right Cessation
-
2018
- 2018-02-01 IL IL257296A patent/IL257296B2/en unknown
- 2018-03-09 CO CONC2018/0002534A patent/CO2018002534A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016304737B2 (en) | 2021-03-11 |
| JP6857647B2 (ja) | 2021-04-14 |
| IL257296A (en) | 2018-03-29 |
| EP3334427A4 (en) | 2019-02-06 |
| US20180235942A1 (en) | 2018-08-23 |
| CA2994952A1 (en) | 2017-02-16 |
| CN108135889A (zh) | 2018-06-08 |
| IL257296B (en) | 2022-10-01 |
| CO2018002534A2 (es) | 2018-05-31 |
| TW201717944A (zh) | 2017-06-01 |
| AU2016304737A1 (en) | 2018-02-22 |
| KR20180048707A (ko) | 2018-05-10 |
| MX2018001720A (es) | 2018-09-06 |
| TWI763632B (zh) | 2022-05-11 |
| MX394213B (es) | 2025-03-24 |
| EP3334427A1 (en) | 2018-06-20 |
| JP2018522920A (ja) | 2018-08-16 |
| IL257296B2 (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| MX2024010140A (es) | Nuevos metodos. | |
| PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| MX2022006258A (es) | Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina. | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| GT201700056A (es) | Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| SMT201300095B (it) | Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| EA201890507A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| MX379253B (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| MX2015014939A (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| ECSP13012369A (es) | Agentes terapéuticos 976 | |
| MX387263B (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| MX372644B (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |